Effects of Kangai injection combined with bevacizumab and DP scheme on efficacy and serum tumor markers and prognosis of NSCLC

doi:10.3969/j.issn.1004-583X.2021.06.007

Abstract

Abstract:

Objective To observe the efficacy of Kangai injection combined with bevacizumab and docetaxel plus cisplatin (DP scheme) on efficacy and serum tumor markers and prognosis of non-small cell lung cancer(NSCLC). Methods Totally 95 NSCLC patients admitted to our hospital from October 2017 to October 2020 were retrospectively selected as the research objects. According to the treatment methods, the patients were divided into three groups: 30 patients were treated with DP alone (control group), 34 patients were treated with Kangai injection combined with DP (observation group 1), and 31 patients were treated with Kangai injection combined with bevacizumab and DP scheme (observation group 2). Short-term efficacy, serum biochemical factors (VEGF, CA199, CEA, CYFRA21-1), quality of life (FACT-L) and survival time were compared. Results Short-term efficacy in three groups was significantly different (P<0.05), and effective rate in observation group 1 and group 2 was significantly higher than that in control group (P<0.05). After treatment, levels of serum VEGF, CA199, CEA and CYFRA21-1 in three groups were significantly decreased (P<0.05), the order from high to low: control group> observation group 1> observation group 2 (P<0.05). FACT-L score T1 in the three groups decreased to the lowest (P<0.05). At T1 and T2, the order FACT-L scores from high to low: observation group 2 > observation group 1 >control group (P<0.05). Survival time of cases in the observation group 2 was the highest in the three groups (P<0.05). Conclusion In the treatment of NSCLC, Kangai injection combined with bevacizumab and DP scheme can enhance the clinical effective rate, improve the quality of life and prolong the survival time.

Key words: carcinoma, non-small cell lung, kangai injection, bevacizumab, quality of life, survival time

CLC Number:

R734.2

Wang Ai. Effects of Kangai injection combined with bevacizumab and DP scheme on efficacy and serum tumor markers and prognosis of NSCLC[J]. Clinical Focus, 2021, 36(6): 517-521.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.06.007

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I6/517

Figures/Tables 4

References 13

[1]	Li HR, Qiu BQ, Gao J, et al. Overexpression of EI2BL promoted human non-small cell lung cancer progression by inducing cell EMT phenotype[J]. J Clin Pathol, 2020, 73(3):139. doi: 10.1136/jclinpath-2019-205778 URL
[2]	Weiss JM, Pennell N, Deal AM, et al. Nab-aclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy[J]. Cancer, 2020, 126(5):1060-1067. doi: 10.1002/cncr.v126.5 URL
[3]	Chen L, Kim JS, Antonio BS, et al. Safety outcomes in advanced non-small-cell lung cancer patients treated with first-line platinum-based regimens in the United States[J]. J Thorac Dis, 2019, 11(11):4474-4483. doi: 10.21037/jtd.2019.11.11 pmid: 31903235
[4]	洪晓华, 王光耀, 刘体勤, 等. 八种中药注射剂联合紫杉醇和顺铂化疗方案治疗非小细胞肺癌的网状Meta分析[J]. 中国全科医学, 2020, 23(26):3311-3323.
[5]	Xu X, Zhou X, Gao C, et al. Nodal promotes the malignancy of non-small cell lung cancer (NSCLC) cells via activation of NF-κB/IL-6 signals[J]. Biol Chem, 2019, 400(6):777-785. doi: 10.1515/hsz-2018-0392 URL
[6]	Wang T, Zhang T, Han X, et al. Impact of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of stage IA adenocarcinoma of the lung: Correlation between computed tomography images and EGFR and KRAS gene mutations[J]. Exp Ther Med, 2015, 9(6):2095-2103. doi: 10.3892/etm.2015.2422 URL
[7]	Nishino M, Jackman DM, Hatabu H, et al. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy[J]. AJR Am J Roentgenol, 2010, 195(3):221-228.
[8]	潘雁, 徐云华, 王韡旻, 等. FACT-L中文版4.0用于肺癌化疗患者生命质量测定的分析研究[J]. 中国卫生资源, 2010, 13(6):265-267.
[9]	杨思琦, 姚颐, 宋启斌. FACT-L中文版4.非小细胞肺癌脑转移患者临床特征及预后影响因素分析[J]. 中国医药导报, 2020, 17(32):10-14+22.
[10]	Matsui A, Morise M, Tanaka I, et al. Primary prophylaxis indication for docetaxel induced febrile neutropenia in elderly patients with non-small cell lung cancer[J]. Cancer Invest, 2020, 38(7):1-19. doi: 10.1080/07357907.2019.1695816 URL
[11]	Duan L, Perez RE, Chastain PD, et al. JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells[J]. Oncogene, 2019, 38(28):5643-5657. doi: 10.1038/s41388-019-0814-6 pmid: 30967636
[12]	马骁, 何璇, 李浩田, 等. 康艾注射液联合TACE治疗原发性肝癌的Meta分析[J]. 中成药, 2019, 41(7):1564-1572.
[13]	中国临床肿瘤学会血管靶向治疗专家委员会, 中国临床肿瘤学会非小细胞肺癌专家委员会, 中国临床肿瘤学会非小细胞肺癌抗血管生成药物治疗专家组. 晚期非小细胞肺癌抗血管生成药物治疗中国专家共识(2020版)[J]. 中华医学杂志, 2020, 100(46):3659-3673.

组别	例数	CR	PR	SD	PD	有效率(%)
对照组	30	7(23.33)	6(20.00)	12(40.00)	6(20.00)	43.33(13/30)
观察组一	34	11(32.35)	13(38.24)	7(20.59)	3(8.82)	70.59(24/34)^*
观察组二	31	10(32.26)	15(48.39)*	4(12.90)	2(6.45)	80.65(25/31)^*
H/χ²值		6.478				8.249
P值		0.039				0.004

组别	例数	CR	PR	SD	PD	有效率(%)
对照组	30	7(23.33)	6(20.00)	12(40.00)	6(20.00)	43.33(13/30)
观察组一	34	11(32.35)	13(38.24)	7(20.59)	3(8.82)	70.59(24/34)^*
观察组二	31	10(32.26)	15(48.39)*	4(12.90)	2(6.45)	80.65(25/31)^*
H/χ²值		6.478				8.249
P值		0.039				0.004

组别	例数	VEGF(mg/L)		CA199(U/ml)		CEA(μg/L)		CYFRA21-1(ng/ml)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	30	221.08±43.35	173.64±31.32^※	87.24±13.34	45.27±8.36^※	110.78±21.85	49.84±8.81^※	14.71±3.31	7.18±1.37^※
观察组一	34	226.88±42.11	143.93±27.35^※*	86.75±14.04	39.63±6.7^※*	106.62±23.06	38.86±6.67^※*	15.12±3.28	5.53±1.10^※*
观察组二	31	220.5±42.52	103.32±20.04^※*△	89.74±12.34	27.66±4.28^※*△	109.79±22.76	30.87±4.56^※*△	14.39±3.42	3.02±0.88^※*△
组间		F=10.878, P<0.01		F=5.386, P<0.01		F=4.575, P<0.05		F=10.725, P<0.01
时点间		F=466.562, P<0.01		F=2127.230, P<0.01		F=1159.593, P<0.01		F=903.779, P<0.01
组间·时点间		F=26.813, P<0.01		F=29.744, P<0.01		F=6.448, P<0.01		F=11.904, P<0.01

组别	例数	VEGF(mg/L)		CA199(U/ml)		CEA(μg/L)		CYFRA21-1(ng/ml)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	30	221.08±43.35	173.64±31.32^※	87.24±13.34	45.27±8.36^※	110.78±21.85	49.84±8.81^※	14.71±3.31	7.18±1.37^※
观察组一	34	226.88±42.11	143.93±27.35^※*	86.75±14.04	39.63±6.7^※*	106.62±23.06	38.86±6.67^※*	15.12±3.28	5.53±1.10^※*
观察组二	31	220.5±42.52	103.32±20.04^※*△	89.74±12.34	27.66±4.28^※*△	109.79±22.76	30.87±4.56^※*△	14.39±3.42	3.02±0.88^※*△
组间		F=10.878, P<0.01		F=5.386, P<0.01		F=4.575, P<0.05		F=10.725, P<0.01
时点间		F=466.562, P<0.01		F=2127.230, P<0.01		F=1159.593, P<0.01		F=903.779, P<0.01
组间·时点间		F=26.813, P<0.01		F=29.744, P<0.01		F=6.448, P<0.01		F=11.904, P<0.01

组别	例数	T0	T1	T2
对照组	30	135.23±21.30	101.37±16.54^※	124.16±18.93^※#
观察组一	34	135.75±21.20	113.72±18.63^※*	144.23±20.48^※#*
观察组二	31	136.13±21.33	121.54±18.84^※*△	152.23±20.81^※#*△
组间		F=7.537,P<0.01
时点间		F=6.501,P<0.05
组间·时点间		F=17.947,P<0.01